Efficacy and safety of artemether-lumefantrine and dihydroartemisinin- piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children aged less than five years: Results of an open-label, randomized, single-centre study

Malaria Journal

Volumn 13, Issue 1, 2014, Pages

  Ogutu, Bernhards R ^a   Onyango, Kevin O ^a   Koskei, Nelly ^a   Omondi, Edgar K ^a   Ongecha, John M ^a   Otieno, Godfrey A ^a   Obonyo, Charles ^a   Otieno, Lucas ^a   Eyase, Fredrick ^a   Johnson, Jacob D ^a   Omollo, Raymond ^a   Perkins, Douglas J ^b   Akhwale, Willis ^c   Juma, Elizabeth ^a,c  

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c Ministry of Public Health and Sanitation   (Kenya)

Author keywords

Artemether lumefantrine; Dihydroartemisinin piperaquine; Uncomplicated Plasmodium falciparum malaria

Indexed keywords

ANTIMALARIAL AGENT; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ DERIVATIVE; DIHYDROARTEMISININ; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE; PIPERAQUINE; QUINOLINE DERIVATIVE;

ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; DRUG EFFECT; HUMAN; INFANT; KENYA; MALARIA FALCIPARUM; PARASITOLOGY; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; TABLET;

ANTIMALARIALS; ARTEMISININS; CHILD, PRESCHOOL; DRUG COMBINATIONS; ETHANOLAMINES; FLUORENES; HUMANS; INFANT; KENYA; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; QUINOLINES;

EID: 84892909196     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-13-33     Document Type: Article

References (42)

1. World Malaria Report, World Malaria Report 2011 http://www.who.int/ entity/malaria/world-malaria-report-2011/9789241564403-eng.pdf
2. World Health Organization, Guidelines for the Treatment of Malaria 2 2010 http://www.who.int/malaria/publications/atoz/9789241547925/en/index.html
3. Artemisinin resistance in Plasmodium falciparum malaria. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ, N Engl J Med 2009 361 455 67 10.1056/NEJMoa0808859 19641202
4. Evidence of artemisinin-resistant malaria in western Cambodia. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM, Artemisinin Resistance in Cambodia 1 (ARC1) Study Consortium, N Engl J Med 2008 359 2619 20 10.1056/NEJMc0805011 19064625
5. Artemisinin-resistant malaria in Asia. Noedl H, Socheat D, Satimai W, N Engl J Med 2009 361 540 541 10.1056/NEJMc0900231 19641219
6. High level of resistance of Plasmodium falciparum to sulfadoxine- pyrimethamine in children in Tanzania. Rønn AM, Msangeni HA, Mhina J, Wernsdorfer WH, Bygbjerg IC, Trans R Soc Trop Med Hyg 1996 90 179 81 10.1016/S0035-9203(96)90129-7 8761583
7. Artesunate combinations for treatment of malaria: meta-analysis. Adjuik M, Babiker A, Garner P, Olliaro P, Taylor W, White N, International Artemisinin Study Group, Lancet 2004 363 9 17 14723987
8. Artemether/lumefantrine in the treatment of uncomplicated falciparum malaria. Kokwaro G, Mwai L, Nzila A, Expert Opin Pharmacother 2007 8 75 94 10.1517/14656566.8.1.75 17163809
9. Artesunate reduces but does not prevent posttreatment transmission of Plasmodium falciparum to Anopheles gambiae. Targett G, Drakeley C, Jawara M, von Seidlein L, Coleman R, Deen J, Pinder M, Doherty T, Sutherland C, Walraven G, Milligan P, J Infect Dis 2001 183 1254 59 10.1086/319689 11262208
10. Effects of artemisinin derivatives on malaria transmissibility. Price RN, Nosten F, Luxemburger C, ter Kuile FO, Paiphun L, Chongsuphajaisiddhi T, White NJ, Lancet 1996 347 1654 58 10.1016/S0140-6736(96)91488-9 8642959
11. Efficacy and safety of artemether lumefantrine in the treatment of acute uncomplicated Plasmodium falciparum malaria: a pooled analysis. Makanga M, Bassat Q, Falade CO, Premji ZG, Krudsood S, Hunt P, Walter V, Beck HP, Marrast AC, Cousin C, Rosenthal PJ, Am J Trop Med Hyg 2011 85 793 804 10.4269/ajtmh.2011.11-0069 22049029
12. Coartem®: A decade of patient-centric malaria management. Hamed K, Grueninger H, Expert Rev Anti Ther 2012 10 645 659 10.1586/eri.12.51
13. A reversal in reductions of child mortality in western Kenya, 2003-2009. Hamel MJ, Adazu K, Obor D, Sewe M, Vulule J, Williamson JM, Slutsker L, Feikin DR, Laserson KF, Am J Trop Med Hyg 2011 85 597 605 10.4269/ajtmh.2011.10-0678 21976557
14. Safety of artemether-lumefantrine in pregnant women with malaria: results of a prospective cohort study in Zambia. Manyando C, Mkandawire R, Puma L, Sinkala M, Mpabalwani E, Njunju E, Gomes M, Ribeiro I, Walter V, Virtanen M, Schlienger R, Cousin M, Chipimo M, Sullivan FM, Malar J 2010 9 249 10.1186/1475-2875-9-249 20809964
15. Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial. Abdulla S, Sagara I, Borrmann S, D'Alessandro U, González R, Hamel M, Ogutu B, Mårtensson A, Lyimo J, Maiga H, Sasi P, Nahum A, Bassat Q, Juma E, Otieno L, Björkman A, Beck HP, Andriano K, Cousin M, Lefèvre G, Ubben D, Premji Z, Lancet 2008 372 1819 1827 10.1016/S0140-6736(08)61492-0 18926569
16. The content of African diets is adequate to achieve optimal efficacy with fixed-dose artemether-lumefantrine: a review of the evidence. Premji ZG, Abdulla S, Ogutu B, Ndong A, Falade CO, Sagara I, Mulure N, Nwaiwu O, Kokwaro G, Malar J 2008 7 244 10.1186/1475-2875-7-244 19032767
17. Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda. Bukirwa H, Yeka A, Kamya MR, Talisuna A, Banek K, Bakyaita N, Rwakimari JB, Rosenthal PJ, Wabwire-Mangen F, Dorsey G, Staedke SG, PLoS Clin Trials 2006 1 7 10.1371/journal.pctr.0010007 16871329
18. A randomized open study to assess the efficacy and tolerability of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Cambodia. Janssens B, van Herp M, Goubert L, Chan S, Uong S, Nong S, Socheat D, Brockman A, Ashley EA, Van Damme W, Trop Med Int Health 2007 12 251 259 10.1111/j.1365-3156.2006.01786.x 17300633
19. Safety and efficacy of dihydroartemisinin-piperaquine versus Artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children. Nambozi M, Van Geertruyden JP, Hachizovu S, Chaponda M, Mukwamataba D, Mulenga M, Ubben D, D'Alessandro U, Malar J 2011 10 50 10.1186/1475-2875-10-50 21352609
20. ICH Harmonized Tripartite guideline, Guidelines for Good Clinical practiceE6 (R1) 1996 Current Step 4 version. http://www.ich.org/fileadmin/ Public-Web-Site/ICH-Products/Guidelines/Efficacy/E6-R1/Step4/E6-R1-Guideline.pdf
21. Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster, Trans R Soc Trop Med Hyg 2000 94 1 1 90 10.1016/S0035-9203(00) 90413-9 11103309
22. World Health Organization, Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria Geneva: WHO WHO/HTM/RBM/2003.50 2003
23. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. Kamya MR, Yeka A, Bukirwa H, Lugemwa M, Rwakimari JB, Staedke SG, Talisuna AO, Greenhouse B, Nosten F, Rosenthal PJ, Wabwire-Mangen F, Dorsey G, PLoS Clin Trials 2007 2 20 10.1371/journal.pctr. 0020020 17525792
24. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. Wabwire-Mangen F, Bukirwa H, Rwakimari JB, Staedke SG, Rosenthal PJ, Lugemwa M, Yeka A, Dorsey G, Kamya MR, Talisuna A, PLoS One 2008 3 2390 10.1371/journal.pone.0002390 18545692
25. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Ezzet F, van Vugt M, Nosten F, Looareesuwan S, White NJ, Antimicrob Agents Chemother 2000 44 697 704 10.1128/AAC.44.3.697-704.2000 10681341
26. Product monograph 2010 [ http://www.coartem.com/product-monograph.htm ] Coartem® -artemether/lumefantrine
27. Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Hung TY, Davis TM, Ilett KF, Karunajeewa H, Hewitt S, Denis MB, Lim C, Socheat D, Br J Clin Pharmacol 2004 57 253 262 14998421
28. Marked variation in MSP-119 antibody responses to malaria in western Kenyan highlands. Badu K, Afrane YA, Larbi J, Stewart VA, Waitumbi J, Angov E, Ong'echa JM, Perkins DJ, Zhou G, Githeko A, Yan G, BMC Infect Dis 2012 12 50 10.1186/1471-2334-12-50 22380785
29. Kenya malaria indicator survey (DoMC) 2010 http://measuredhs.com/pubs/ pdf/MIS7/MIS7.pdf
30. Descriptive study on the efficacy of artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Sudan. Elamin SB, Awad AI, Eltayeb IB, Elmardi KA, Hassan AH, Mohamed AO, Malik EM, Mohamad TA, Eur J Clin Pharmacol 2010 66 231 237 10.1007/s00228-009-0750-4 20187287
31. A randomized, open-label, comparative efficacy trial of Artemether-lumefantrine suspension versus Artemether-lumefantrine tablets for treatment of uncomplicated Plasmodium falciparum malaria in children in western Kenya. Juma EA, Obonyo CO, Akhwale WS, Ogutu BR, Malar J 2008 7 262 10.1186/1475-2875-7-262 19102746
32. Resistance to artemisinin derivatives along the Thai-Cambodian border. Wkly Epidemiol Rec 2007 82 360 17933087
33. WHO, The status of drug-resistant malaria along the Thailand-Myanmar border http://www.who.int/malaria/publications/atoz/drug-resistance-myanmar- thailand-border-may-2012.pdf
34. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. Arinaitwe E, Sandison TG, Wanzira H, Kakuru A, Homsy J, Kalamya J, Kamya MR, Vora N, Greenhouse B, Rosenthal PJ, Tappero J, Dorsey G, Clin Infect Dis 2009 49 1629 1637 10.1086/647946 19877969
35. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Ratcliff A, Siswantoro H, Kenangalem E, Maristela R, Wuwung RM, Laihad F, Ebsworth EP, Anstey NM, Tjitra E, Price RN, Lancet 2007 369 757 765 10.1016/S0140-6736(07)60160-3 17336652
36. Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. Bassat Q, Mulenga M, Tinto H, Piola P, Borrmann S, Menéndez C, Nambozi M, Valéa I, Nabasumba C, Sasi P, Bacchieri A, Corsi M, Ubben D, Talisuna A, D'Alessandro U, PLoS One 2009 4 7871 10.1371/journal.pone.0007871 19936217
37. Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis. Zwang J, Ashley EA, Karema C, D'Alessandro U, Smithuis F, Dorsey G, Janssens B, Mayxay M, Newton P, Singhasivanon P, Stepniewska K, White NJ, Nosten F, PLoS One 2009 4 6358 10.1371/journal.pone.0006358 19649267
38. Efficacy and safety of dihydroartemisinin-piperaquine. Myint HY, Ashley EA, Day NP, Nosten F, White NJ, Trans R Soc Trop Med Hyg 2007 101 858 866 10.1016/j.trstmh.2007.05.018 17659311
39. Dispersible formulation of artemether/lumefantrine: specifically developed for infants and young children. Abdulla S, Sagara I, Malar J 2009 8 1 7 10.1186/1475-2875-8-7
40. The clinical efficacy of artemether/lumefantrine (Coartem). Makanga M, Krudsood S, Malar J 2009 8 1 5 10.1186/1475-2875-8-5
41. Quality control of active ingredients in artemisinin-derivative antimalarials within Kenya and DR Congo. Atemnkeng MA, De Cock K, Plaizier-Vercammen J, Trop Med Int Health 2007 12 68 74 17207150
42. Post-marketing assessment of content and efficacy of preservatives in artemisinin-derived antimalarial dry suspensions for paediatric use. Atemnkeng MA, De Cock K, Plaizier-Vercammen J, Malar J 2007 6 12 10.1186/1475-2875-6-12 17257400